drugset / Trial / NCT00888004

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients

NCT00888004

Phase 2 Completed 28 enrolled Novartis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.

Timeline

Start
2009-03
Primary completion
2009-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavoglurant Small molecule 25 mg Oral
Subject Mavoglurant Small molecule 150 mg Oral